MedTrace Logo

Extension Study to Assess the Safety and Efficacy of Pasireotide in Participants With Cushing's Disease

NCT00171951 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2021-06-02

Study results available
· View outcomes & findings →

Summary

Cushing's disease is a rare serious condition that is caused by an adrenocorticotropic hormone (ACTH) secreting pituitary adenoma. This study assessed the long-term safety and efficacy of pasireotide in participants with Cushing's disease.

Conditions

  • Cushing Disease

Interventions

DRUG

Pasireotide

Pasireotide 600 μg or 900 μg was administered as an SC injection.

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticlas · Novartis Pharmaceuticals

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-08-13
Primary Completion
2013-07-08
Completion
2013-07-08
FDA Drug
Yes

Countries

  • United States
  • France
  • Germany
  • Italy
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00171951 on ClinicalTrials.gov